Home Cart Sign in  
Chemical Structure| 19083-00-2 Chemical Structure| 19083-00-2

Structure of gracillin
CAS No.: 19083-00-2

Chemical Structure| 19083-00-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gracillin is a kind of steroidal saponin isolated and purified from the roots of Dioscorea opposita Thunb. and the root bark of wild yam Dioscorea nipponica with antitumor agent.

Synonyms: NSC 698787

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of gracillin

CAS No. :19083-00-2
Formula : C45H72O17
M.W : 885.04
SMILES Code : C[C@@]12[C@]([C@@H]3C)([H])[C@](O[C@]34CC[C@@H](C)CO4)([H])C[C@@]1([H])[C@@](CC=C5[C@@]6(CC[C@H](O[C@@](O[C@H](CO)[C@@H](O)[C@@H]7O[C@]([C@@H]([C@@H](O)[C@@H]8O)O)([H])O[C@@H]8CO)([H])[C@@H]7O[C@@](O[C@@H](C)[C@H](O)[C@H]9O)([H])[C@@H]9O)C5)C)([H])[C@]6([H])CC2
Synonyms :
NSC 698787
MDL No. :MFCD28978176

Safety of gracillin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
H460 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
PC9/ER 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
PC9/GR 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
DU145/R 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
SK-MES-1/R 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
H460/R 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
H226B/R 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
H1299 10 μM 3 days inhibited mitochondrial dehydrogenase activity and induced apoptosis Cell Death Dis. 2019 Oct 24;10(11):810
RBL-2H3 cells 91.6 mg/g 16 hours To evaluate the effect of gracillin on IL-4 mRNA expression, results showed that DQEA significantly inhibited PMA/ionomycin-induced IL-4 mRNA expression Nutrients. 2017 Dec 5;9(12):1324
H9C2 cells 5 μM and 20 μM 24 hours Gracillin could protect H9C2 cells from CoCl2-induced oxidative stress injury, increase SOD and LDH activities, and decrease MDA content. Heliyon. 2023 Mar 9;9(3):e14353
BEAS-2B cells 0.25, 0.5, 1, 2, 4 μmol/L 24 hours To evaluate the antiproliferative activity of gracillin on BEAS-2B cells, the results showed that gracillin had almost no effect on the proliferation of BEAS-2B cells. Front Oncol. 2022 Mar 22;12:851300
A549 cells 0.25, 0.5, 1, 2, 4 μmol/L 24 hours To evaluate the antiproliferative activity of gracillin on A549 cells, the results showed that gracillin significantly inhibited the cell viability of A549 in a concentration-dependent manner with an IC50 value of 2.421 mmol/L. Front Oncol. 2022 Mar 22;12:851300
SGC7901 cells 0–15 μM inhibited cell proliferation Front Pharmacol. 2021 Sep 24;12:669199
BGC823 cells 5 μM 48 hours inhibited cell proliferation, induced TIPE2 expression Front Pharmacol. 2021 Sep 24;12:669199
RBL-2H3 cells 10 µM 1 hour To investigate the inhibitory effect of gracillin on IgE-mediated β-hexosaminidase release in RBL-2H3 cells. Results showed that gracillin significantly suppressed IgE-induced β-hexosaminidase release. Nutrients. 2018 Sep 1;10(9):1205
RBL-2H3 cells 10 µM 30 minutes To investigate the inhibitory effect of gracillin on PI-induced IL-4 expression in RBL-2H3 cells. Results showed that gracillin significantly suppressed PI-induced IL-4 mRNA expression. Nutrients. 2018 Sep 1;10(9):1205
BEAS-2B cells 0.25, 0.5, 1, 2, 4 μmol/L 48 hours Compared with the control group, gracillin had almost no effect on the viability of BEAS-2B cells. Drug Des Devel Ther. 2021 Jan 20;15:233-243
A549 cells 0.25, 0.5, 1, 2, 4 μmol/L 12, 24, 48 hours Gracillin significantly inhibited the proliferation of A549 cells in a concentration-dependent and time-dependent manner with an IC50 value of 2.54 μmol/L and induced morphological changes. Flow cytometry analysis showed that the apoptosis rate of A549 cells was significantly increased (p < 0.05), and the cells were arrested in the S phase. The intracellular calcium concentration was elevated (p < 0.01), and the mitochondrial membrane potential was significantly decreased (p < 0.01). Additionally, the expression levels of Bax, caspase-3, cleaved caspase-3, and cytochrome C were dramatically up-regulated, while Bcl-2 was down-regulated (p < 0.05). Drug Des Devel Ther. 2021 Jan 20;15:233-243
MDA-MB-231 5 μM 6 h Inhibition of glycolysis, significantly reducing lactate production. Cancers (Basel). 2020 Apr 8;12(4):913
MDA-MB-468 5 μM 6 h Inhibition of glycolysis, significantly reducing lactate production. Cancers (Basel). 2020 Apr 8;12(4):913
H226B 5 μM 8 h Inhibition of glycolysis-associated metabolites production, including 3-phosphoglycerate, phosphoenolpyruvate, pyruvate, and lactate. Cancers (Basel). 2020 Apr 8;12(4):913
H460 5 μM 8 h Inhibition of glycolysis-associated metabolites production, including 3-phosphoglycerate, phosphoenolpyruvate, pyruvate, and lactate. Cancers (Basel). 2020 Apr 8;12(4):913
BGC823/TIPE2−/− cells 5 μM 48 hours inhibited cell proliferation, induced TIPE2 expression Front Pharmacol. 2021 Sep 24;12:669199
RKO 0, 2.5, 5.0, 10.0 µmol/L 36 hours To evaluate the apoptosis-inducing effect of gracillin on human colorectal cancer cells. The results showed that gracillin stimulated apoptosis in RKO cells in a dose-dependent manner. J Cell Mol Med. 2021 Jan;25(2):801-812
HCT116 0, 2.5, 5.0, 10.0 µmol/L 36 hours To evaluate the apoptosis-inducing effect of gracillin on human colorectal cancer cells. The results showed that gracillin stimulated apoptosis in HCT116 cells in a dose-dependent manner. J Cell Mol Med. 2021 Jan;25(2):801-812
SW480 0, 2.5, 5.0, 10.0 µmol/L 48 hours To evaluate the inhibitory effect of gracillin on the proliferation of human colorectal cancer cells. The results showed that gracillin significantly inhibited the viability of SW480 cells with an IC50 value of 2.671 µmol/L. J Cell Mol Med. 2021 Jan;25(2):801-812
RKO 0, 2.5, 5.0, 10.0 µmol/L 48 hours To evaluate the inhibitory effect of gracillin on the proliferation of human colorectal cancer cells. The results showed that gracillin significantly inhibited the viability of RKO cells with an IC50 value of 3.118 µmol/L. J Cell Mol Med. 2021 Jan;25(2):801-812
HCT116 0, 2.5, 5.0, 10.0 µmol/L 48 hours To evaluate the inhibitory effect of gracillin on the proliferation of human colorectal cancer cells. The results showed that gracillin significantly inhibited the viability of HCT116 cells with an IC50 value of 5.473 µmol/L. J Cell Mol Med. 2021 Jan;25(2):801-812

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SKH-1 hairless mice DNCB-induced AD-like skin lesions model Topical application 1% Twice a day for 2 weeks To investigate the therapeutic effect of gracillin on DNCB-induced AD-like skin lesions. Results showed that gracillin significantly improved AD-like skin symptoms, reduced epidermal thickening and mast cell infiltration, and improved skin barrier function. Nutrients. 2018 Sep 1;10(9):1205
NOD/SCID mice MDA-MB-231 breast cancer cell line xenograft model Subcutaneous injection 20 mg/kg Twice a week for 2 weeks Gracillin significantly inhibited tumor growth without causing significant changes in body weight or other toxicities. Cancers (Basel). 2020 Apr 8;12(4):913
BALB/c nude mice HCT116 xenograft model Intraperitoneal injection 1 mg/kg or 2 mg/kg Every other day until the tumor volume reached ~100 mm^3 To evaluate the inhibitory effect of gracillin on colorectal cancer tumor growth in vivo. The results showed that gracillin significantly inhibited tumor growth with no apparent physiological toxicity. J Cell Mol Med. 2021 Jan;25(2):801-812
BALB/c mice A549 cell xenograft model Intraperitoneal injection High dose 20 mg/kg, medium dose 10 mg/kg, low dose 5 mg/kg 6 days a week for two consecutive weeks To evaluate the anti-tumor activity of gracillin in the A549 cell xenograft model, the results showed that gracillin significantly inhibited tumor growth in a dose-dependent manner. Front Oncol. 2022 Mar 22;12:851300
NOD/SCID mice Xenograft models Oral 10 mg/kg 6 days per week for 2 weeks Significantly reduced the growth of xenograft tumors with no obvious toxicity Cell Death Dis. 2019 Oct 24;10(11):810

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.13mL

0.23mL

0.11mL

5.65mL

1.13mL

0.56mL

11.30mL

2.26mL

1.13mL

References

 

Historical Records

Categories